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Much has been learned about the mechanisms underlying tumor angiogenesis, and therapies that target vascular endothelial
growth factor (VEGF) to limit tumor angiogenesis and subsequent disease progression have recently been approved. However, the
transcriptional mechanisms that regulate pathological angiogenesis remain largely unknown. FoxC2, a member of the Forkhead
box (Fox) transcription factor family, is critical for vascular formation during development, and recent studies have shown that
FoxC2 is expressed in the endothelium of tumors in both humans and mice. In a B16 mouse melanoma model, Foxc2 deﬁciency
reduced tumor growth and neovascularization and was associated with impairments in mural-cell coverage and increases in
endothelial-cell apoptosis in tumor blood vessels. FoxC2 is also expressed by tumor cells in human breast, colonic, and esophageal
cancer and participates in the epithelial-mesenchymal transition (EMT), a key process that leads to the invasion and metastasis of
aggressive tumors. Collectively, these observations suggest that FoxC2 is essential for tumor angiogenesis and disease progression
and that FoxC2 may be a viable target for cancer therapy.
1.Introduction
Tumor angiogenesis is a crucial contributor to tumor devel-
opment and progression [1] because tumor blood vessels
supplyoxygenandnutrientstothetumortissueandfacilitate
cancer cell invasion and metastasis. Tumor vessels are usually
disorganized and excessively branched [2–4], and formation
of the tumor vasculature involves complex interactions
between tumor cells and their microenvironment that are
controlled by numerous angiogenic factors secreted from
both tumor cells and other cells in the tumor microenvi-
ronment. The mechanisms by which proangiogenic factors
such as vascular endothelial growth factor (VEGF) promote
tumor angiogenesis have been intensively studied [2–4];
however, the transcription factors that participate in this
process remain incompletely understood. The FoxC2 tran-
scription factor is a newly recognized regulator of tumor
angiogenesis and metastasis, and this paper summarizes
what is currently known about the role of FoxC2 in
cancer.
2.Forkhead TranscriptionFactorsinCancer
The Fox (Forkhead box) transcription factors form a large
family of proteins with similar DNA-binding domains that
are evolutionarily conserved from yeast to humans [5–7];
other functional regions of Fox proteins, such as the transac-
tivation and transrepression domains, are largely divergent.
The consensus, seven-nucleotide core sequence bound by
monomeric Fox proteins is 5 -(G/A)(T/C)(A/C)AA(C/T)A-
3  [8, 9], and Fox proteins are distributed among 19 sub-
families (FoxA to FoxS) based on similarities in their DNA-
binding domains. Uppercase letters are used to designate
human Fox genes (e.g., FoxC2), the ﬁrst letter is capitalized
for mouse genes (e.g., FoxC2), and the ﬁrst and subclass
letters are capitalized for chordates (e.g., FoxC2).
Fox proteins have many essential roles in embryonic
development, and the mutation or dysregulation of FOX
genes is often associated with disease, including cancer [10].
FoxM1 is expressed in glioma and pancreatic cancer cells
and promotes angiogenesis by regulating VEGF expression2 Journal of Oncology
[11, 12], FoxO1/3/4 act as tumor suppressors in prostate
cancer and leukemia [13, 14], and recent evidence suggests
that FoxC2 is a key factor in tumor development and disease
progression. Thus, the elucidation of FOX gene function will
likely identify new strategies for the treatment of cancer.
3. Role of FoxC2 inVascular Development
andAngiogenesis
Murine FoxC2 is highly expressed in blood endothelial cells
during embryonic development [16–19]. FoxC2 contributes
to arterial cell speciﬁcation in the early developing embryo
as a downstream regulator of the Notch signaling pathway
[18, 20–22], and FoxC2 participates in angiogenesis [23,
24] through the activity of its downstream targets CXC-
chemokine receptor 4 (CXCR4) and integrin β3[ 25, 26].
The transcriptional activity of FoxC2 in vascular endothelial
cells is modulated by VEGF signaling [20], and FoxC2
is critical for the migration of endothelial cells toward
VEGF or stromal-cell-derived factor 1 (SDF-1) and for
the formation of microvessels in vitro [25, 26]. Recent
studies have shown that the activity of FoxC2 and the Ets
transcription factor Etv2 combine to regulate endothelial-
speciﬁc gene expression during early development, including
Flk1, Tie2, and VE-cadherin [27], and the Ets transcription
factors are known to be important for tumor angiogenesis
[28], but whether FoxC2 and Etv2 also coregulate tumor
vessel formation has yet to be determined.
The importance of epigenetic changes during the regu-
lation of angiogenesis, including the methylation or histone
acetylation of angiogenesis-associated genes, is becoming
increasingly apparent [29]; for example, the histone deacety-
lase (HDAC) SIRT1 induces the sprouting and branching
of endothelial cells by deacetylating Foxo1 [30]. SIRT1
also regulates the angiogenic activity of endothelial cells by
deacetylating the Notch1 intracellular domain (NICD) [31],
and a Notch transcriptional activation complex containing
the NICD physically and functionally interacts with FoxC2
[20]. Collectively, these observations suggest that FoxC2 may
be involved in SIRT1-mediated transcriptional control of
angiogenesis.
FoxC2 is also expressed in lymphatic endothelial cells
during development [32, 33], and mutations in human
FoxC2 are responsible for the autosomal dominant syn-
drome lymphedema distichiasis, which is characterized by
the obstruction of lymph drainage in the limbs and by the
growth of an extra set of eyelashes [34, 35]. Congenital
lymphatic defects are also observed in FoxC2 mutant mice:
heterozygous FoxC2 mutants display hyperplasia of the
lymphatic vessels [36], and homozygous FoxC2 mutants
have defective lymphatic valves and abnormal pericyte
recruitment of lymphatic vessels [33]. The contribution of
FoxC2 to lymphangiogenesis in pathological conditions such
as cancer remains unknown.
4. FoxC2in Tumor Angiogenesis
FoxC2 expression has been detected in the tumor endothe-
lium of both human and mouse melanomas, which suggests
Table 1: Summary of FoxC2 expression and prognosis in human
cancer.
Tumor type Number FoxC2 expression Prognosis
Melanoma
[15] Vascular endothelial cells Not evaluated
Breast, colon
[15] Adenocarcinoma Not evaluated
Esophageal
[39] 70 Cytoplasm of cancer
cells
5-year survival:
70% FoxC2
(low); 30%
FoxC2 (high)
Breast [40]1 8 Highly aggressive
basal-like tumors Not evaluated
Breast [41]C D 4 4
high/CD24
lowcells Not evaluated
that FoxC2 has a role in tumor angiogenesis (Table 1)[ 15].
Homozygous mutations of FoxC2 lead to perinatal lethality,
so the role of FoxC2 in melanoma was conﬁrmed by sub-
cutaneously implanting mouse B16 melanoma cells in wild-
type and heterozygous FoxC2 mutant (FoxC2+/–) mice.
Tumor growth and angiogenesis were remarkably lower in
the FoxC2+/– mutants (Figure 1)[ 15], which conﬁrms that
FoxC2 has an essential role in tumor angiogenesis. Matrix
metalloproteinase (MMP) 2 expression was also diminished
in B16 tumors from FoxC2+/– mice [15], which is consistent
with evidence that MMP2 is important for tumor growth
and angiogenesis [37, 38]. The expression of the lymphatic
endothelial markers Prox1 and Lyve1 were unchanged [15],
despite evidence that FoxC2 is expressed in lymphatic endo-
thelial cells.
VEGF-A expression was also impaired in B16 tumors
from FoxC2+/– mice [15], and this decline likely limits tu-
mor neovascularization. The cells responsible for the decline
in VEGF-A expression have yet to be identiﬁed; however,
autocrine VEGF signaling promotes endothelial cell survival
[42], and smooth muscle α-actin- (αSMA-) positive cancer-
associated ﬁbroblasts (CAFs), which are known to express
VEGF-A in the tumor microenvironment [43–45], were less
c o m m o ni nt u m o r sf r o mF o x C 2 + / –m i c et h a ni nt u m o r s
from wild-type mice [15]. CAFs also secrete stromal cell-
derived factor 1 (SDF-1), which stimulates tumor growth
by activating its receptor, CXCR4, on tumor cells and by
functioning as a chemoattractant for the recruitment of
bone-marrow-derived endothelial progenitor cells that sub-
sequentlypromoteangiogenesis[45].FoxC2isalsoknownto
regulate the CXCR4-dependent mobilization of endothelial
cells and bone-marrow-derived endothelial progenitor cells
[25, 46], so FoxC2 might have a bimodal inﬂuence on the
contribution of bone-marrow-derived cells to tumor angiog-
enesis by increasing both cell mobilization and the SDF-
1-mediated recruitment of mobilized cells to tumors. Fur-
thermore, FoxC2 expression is induced by hypoxia after
ischemia/reperfusion injury in the kidney [47], and the
hypoxic gradient that develops in the tumor microenvi-
ronment increases SDF-1 expression in CAFs and CXCR4
expression in tumor cells [48, 49]; thus, FoxC2 could alsoJournal of Oncology 3
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Figure 1: Tumor development and angiogenesis are impaired in FoxC2+/– mice. (a) Subcutaneous growth of B16 melanoma cells in WT
and FoxC2+/– mice 11 days after injection. The yellow arrow identiﬁes a smaller tumor in a FoxC2+/– mouse. (b) A diﬀerence in tumor
weight between WT and FoxC2+/– mice was observed 11 days after the injection of B16 melanoma cells. The data are from ﬁve independent
experiments and are presented as mean ± SD. Statistical signiﬁcance was evaluated with Student’s t-test. ∗P<0.05 versus WT. (c, d) Tumor
angiogenesis is reduced in FoxC2+/– mice. (c) The total number of capillaries was calculated by counting PECAM-1-positive endothelial
cells in B16 tumors. Statistical signiﬁcance was evaluated with Student’s t-test (∗P<0.05 versus WT). (d) Total vessel density was calculated
bymeasuringtheevaluatedwiththeStudent’st-testPECAM-1-positivevesselarea.StatisticalsigniﬁcancewasevaluatedwithStudent’st-test.
∗P<0.05 versus WT. Adapted from Sano et al. [15].
contribute to tumor angiogenesis through a hypoxia-related
mechanism.
Fibroblasts in the tumor microenvironment are a heter-
ogeneous cell population, and the conventional markers
αSMA and vimentin cannot identify all CAFs [50]. Further-
more, transforming growth factor- (TGF-) β1 can induce
the phenotypic conversion of proliferating vascular endothe-
lial cells into ﬁbroblast-like cells; this endothelial-to-mes-
enchymal transition (EndMT) takes place at the inva-
sive front of tumors in mice [51], and, consequently,
antiangiogenic treatments may limit cancer progression,
in part, by directly inﬂuencing the EndMT in tumor4 Journal of Oncology
vessels. The molecular mechanisms and signaling path-
ways that control EndMT have yet to be elucidated;
however, CAFs can develop directly from cancer cells
through the epithelial-to-mesenchymal transition (EMT)
[52], which is regulated by FoxC2 (as discussed in the
next section). CAFs can also evolve from resident ﬁbrob-
lasts, smooth muscle cells, pericytes, or bone-marrow-
derived mesenchymal stem cells through a mesenchymal-
to-mesenchymal transition (MMT), which is regulated by
tumor-cell-derived factors such as TGF-β, platelet-derived
growth factor (PDGF), and basic ﬁbroblast growth factor
(FGF) [53]; whether FoxC2 participates in the MMT is
unknown.
The declines in tumor growth and vascularity observed
in FoxC2+/– mice were also associated with abnormally
low levels of PDGF-B, which is likely attributable to the
impaired growth of smooth muscle cells surrounding the
tumor blood vessels [15]. The precise role of PDGF signaling
in tumor angiogenesis remains a subject of debate [54];
however, PDGF mediates the maturation and stabilization
of blood vessels during normal vessel growth by regulating
the interaction between endothelial cells and mural cells
(e.g., vascular smooth muscle cells and pericytes) that are
looselyassociatedwiththetumorendothelium,andPDGF-B
inhibition is associated with both the loss of mural cells and
tumor-vessel regression [55] .T h eb l o c k a d eo fb o t hV E G F
and PDGF receptor-β signaling in tumor blood vessels with
kinase inhibitors also induces tumor vessel regression [56,
57],andparacrinesignalingbetweenpericytesandthetumor
endothelium [58] could increase the instability of the tumor
vessels of FoxC2+/– mice by reducing VEGF and PDGF-B
signaling [15].
5.FoxC2inCancerCells
Tumor FoxC2 expression is not restricted to the vasculature
(Table 1)[ 15]. T-MTA-6A tissue-array (NCI/NIH) analysis
revealed the localization of FoxC2 protein in the majority of
breast adenocarcinomas, including lobular and ductal ade-
nocarcinoma, and in about half of colonic adenocarcinomas
[15]. FoxC2 expression has also been reported in esophageal
cancer cells [39], and the survival rate is signiﬁcantly lower
for patients with high levels of FoxC2 expression than for
patients with low levels of FoxC2 expression, which suggests
that FoxC2 could be used as a novel, independent prognosis
factor for patients with esophageal cancer [39]( Table 1).
PatientswithhighlevelsofFoxC2expressionalsohavehigher
levels of MMP2 and MMP9 expression [39].
FoxC2 is an important regulator of EMT, a key pro-
cess that is often activated during tumor progression and
metastasis [59]. FoxC2 expression is signiﬁcantly correlated
with highly aggressive basal-like breast cancers, and FoxC2
overexpression increases the metastatic potential of mouse
mammary carcinoma cells to the lung [40]. The EMT-
inducing transcription factors Twist, Snail, and Goosecoid,
as well as TGF-β, which also induces EMT, can induce
FoxC2 expression in epithelial cells [40, 60], and FoxC2
overexpression promotes mesenchymal diﬀerentiation, as
well as the induction of MMP2 and MMP9 expression [40].
Furthermore, FoxC2 indirectly represses expression of the
epithelial marker E-cadherin, whose loss is considered a
hallmark of EMT [59], and directly downregulates p120-
catenin, a regulatory protein that stabilizes E-cadherin at
the adhesion junctions of epithelial cells [61]. Thus, accu-
mulating evidence indicates that EMT-inductive signaling
molecules, such as TGF-β, stimulate FoxC2 expression in
carcinoma cells along with other EMT-promoting tran-
scription factors and mediates mesenchymal diﬀerentiation,
thereby leading to EMT and metastasis [59]. EMT has also
been linked to the genesis of cancer stem cells [62]; for
example, mammary epithelial cells have been shown to
acquire properties associated with breast cancer stem cells,
including the CD44high/CD24low signature, after undergoing
EMT and to express EMT-inducing transcription factors
such as FoxC2 (Table 1)[ 41]. Notably, tumor cells under-
going EMT acquire a migratory phenotype by ectopically
expressing mesenchymal genes, including FoxC2, which ﬁrst
function in the developing embryo, and tumor cells may
adopt many other developmental signaling pathways that
function in their ancestral precursor cells [63–65]. Thus,
EMT may represent a critical point of convergence between
the signaling paradigms that regulate development and
tumor metastasis.
6.FuturePerspectives
Though we are just beginning to understand how FoxC2
contributes to cancer development and related pathological
conditions, its newly discovered role in tumor angiogenesis
and metastasis suggests that FoxC2 could be an intriguing
target for anticancer therapies. Drug therapies rarely target
transcription factors directly, but a combination of advanced
technologies, such as systems biology and computational
chemistry, could lead to the development of viable tran-
scriptional approaches for preventing cancer development
and progression, as well as other conditions that involve
pathological angiogenesis. For example, FoxM1 is currently
being investigated as a target for cancer therapy [66], and
several chemical inhibitors, including proteasome inhibitors,
o fF o x M 1h a v eb e e nr e p o r t e d[ 67–71], as well as a cell-
penetrating peptide inhibitor of FoxM1 function [72]. The
precise function of FoxC2 in the tumor microenvironment,
including both cancer cells and endothelial cells, must
be better understood before the development of FoxC2-
based therapies can be considered and, consequently, studies
focusing on the mechanisms controlled by FoxC2 are
necessary. The identiﬁcation of relatively small peptides
that can selectively block the function of FoxC2 would
also be a useful step toward designing FoxC2-speciﬁc
inhibitors.
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